Cardiol Therapeutics Inc Class A is experiencing a notable decline, with shares down 2.65% in the last trading session.
In a challenging trading day for Cardiol Therapeutics Inc Class A (CRDL.TO), the stock fell by 2.65%, closing at CA$1.47. This drop reflects investor sentiment amid a lack of significant news to boost confidence in the stock.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$201.73M
52W high
$2.33
52W low
$1.23
1W change
+8.59%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 239.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+239.0% Upside
Current Price
C$1.77
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
47.3%
Annualized
90-Day Vol
61.0%
Annualized
Trend (90d)
-27.6%
Annualized drift
90d Mean
C$1.60
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.71 | C$1.45 โ C$2.02 |
| 60 trading days | C$1.66 | C$1.32 โ C$2.09 |
| 90 trading days | C$1.60 | C$1.21 โ C$2.13 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should remain cautious as Cardiol Therapeutics navigates a volatile market without recent positive catalysts to support its share price.
CRDL.TO down 2.65% in last session
The stock's market cap stands at CA$174 million, indicating its small-cap status and the inherent volatility that comes with it.
Bull case
If Cardiol Therapeutics can effectively leverage its ongoing clinical trials and expand its market presence, thereโs potential for recovery and growth in the long term.
Bear case
Without immediate positive developments or news, the stock may continue to face pressure, especially in a market sensitive to biotech performance.
Market Performance Overview
Cardiol Therapeutics Inc Class A shares fell by 2.65% in the last trading session, reflecting broader market trends that often affect small-cap biotech stocks. With a current market cap of CA$174 million, the stock's movements are particularly sensitive to investor sentiment and market conditions.
Lack of Catalysts
Despite previous announcements regarding clinical trials and shareholder meetings, Cardiol Therapeutics has not released any recent news to support a bullish outlook. Investors may hesitate to buy in the absence of positive developments, contributing to the stock's decline.
Looking Ahead
As Cardiol Therapeutics continues to navigate the complexities of the biotech industry, investors should keep an eye on upcoming announcements. The potential for recovery depends on the company's ability to generate positive news and results from its ongoing clinical trials.
Advertisement
